Literature DB >> 19703714

Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae).

I N Costa1, M B Angeloni, L A Santana, B F Barbosa, M C P Silva, A A Rodrigues, C Rostkowsa, P M Magalhães, J D O Pena, D A O Silva, J R Mineo, E A V Ferro.   

Abstract

Toxoplasma gondii infection during pregnancy may cause severe consequences to the embryo. Current toxoplasmosis treatment for pregnant women is based on the administration of spiramycin or a drug combination as sulphadiazine-pyrimethamine-folinic acid (SPFA) in cases of confirmed fetal infection. However, these drugs are few tolerated and present many disadvantages due to their toxic effects to the host. The aim of this study was to evaluate the effectiveness of different treatments on the vertical transmission of T. gondii, including azithromycin, Artemisia annua infusion, spiramycin and SPFA in Calomys callosus as model of congenital toxoplasmosis. C. callosus females were perorally infected with 20 cysts of T. gondii ME49 strain at the day that a vaginal plug was observed (1st day of pregnancy - dop). Treatment with azithromycin, A. annua infusion, and spiramycin started at the 4th dop, while the treatment with SPFA started at the 14th dop. Placenta and embryonic tissues were collected for morphological and immunohistochemical analyses, mouse bioassay and PCR from the 15th to 20th dop. No morphological changes were seen in the placenta and embryonic tissues from females treated with azithromycin, spiramycin and SPFA, but embryonic atrophy was observed in animals treated with A. annua infusion. Parasites were found in the placenta and fetal (brain and liver) tissues of animals treated with SPFA, A. annua infusion and spiramycin, although the number of parasites was lower than in non-treated animals. Parasites were also observed in the placenta of animals treated with azithromycin, but not in their embryos. Bioassay and PCR results confirmed the immunohistochemical data. Also, bradyzoite immunostaining was observed only in placental and fetal tissues of animals treated with SPFA. In conclusion, the treatment with azithromycin showed to be more effective, since it was capable to inhibit the vertical transmission of T. gondii in this model of congenital toxoplasmosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19703714     DOI: 10.1016/j.placenta.2009.08.002

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  8 in total

1.  Repurposing auranofin for treatment of Experimental Cerebral Toxoplasmosis.

Authors:  Iman Fathy Abou-El-Naga; Nermine Mogahed Fawzy Hussein Mogahed
Journal:  Acta Parasitol       Date:  2021-02-08       Impact factor: 1.440

2.  Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study.

Authors:  Konstantinos Balaskas; Jean Vaudaux; Noémie Boillat-Blanco; Yan Guex-Crosier
Journal:  Med Sci Monit       Date:  2012-05

3.  Enrofloxacin and Toltrazuril Are Able to Reduce Toxoplasma gondii Growth in Human BeWo Trophoblastic Cells and Villous Explants from Human Third Trimester Pregnancy.

Authors:  Rafaela J da Silva; Angelica O Gomes; Priscila S Franco; Ariane S Pereira; Iliana C B Milian; Mayara Ribeiro; Paolo Fiorenzani; Maria C Dos Santos; José R Mineo; Neide M da Silva; Eloisa A V Ferro; Bellisa de Freitas Barbosa
Journal:  Front Cell Infect Microbiol       Date:  2017-07-26       Impact factor: 5.293

Review 4.  A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).

Authors:  Mahbobeh Montazeri; Mehdi Sharif; Shahabeddin Sarvi; Saeed Mehrzadi; Ehsan Ahmadpour; Ahmad Daryani
Journal:  Front Microbiol       Date:  2017-01-20       Impact factor: 5.640

5.  Biogenic Silver Nanoparticles Can Control Toxoplasma gondii Infection in Both Human Trophoblast Cells and Villous Explants.

Authors:  Idessania Nazareth Costa; Mayara Ribeiro; Priscila Silva Franco; Rafaela José da Silva; Thádia Evelyn de Araújo; Iliana Claudia Balga Milián; Luana Carvalho Luz; Pâmela Mendonça Guirelli; Gerson Nakazato; José Roberto Mineo; Tiago W P Mineo; Bellisa Freitas Barbosa; Eloisa Amália Vieira Ferro
Journal:  Front Microbiol       Date:  2021-01-21       Impact factor: 5.640

6.  Azithromycin is able to control Toxoplasma gondii infection in human villous explants.

Authors:  Letícia S Castro-Filice; Bellisa F Barbosa; Mariana B Angeloni; Neide M Silva; Angelica O Gomes; Celene M O S Alves; Deise A O Silva; Olindo A Martins-Filho; Maria C Santos; José R Mineo; Eloisa A V Ferro
Journal:  J Transl Med       Date:  2014-05-19       Impact factor: 5.531

7.  Copaifera spp. oleoresins impair Toxoplasma gondii infection in both human trophoblastic cells and human placental explants.

Authors:  Samuel Cota Teixeira; Guilherme de Souza; Bruna Cristina Borges; Thádia Evelyn de Araújo; Alessandra Monteiro Rosini; Fábio Alves Aguila; Sergio Ricardo Ambrósio; Rodrigo Cassio Sola Veneziani; Jairo Kenupp Bastos; Marcelo José Barbosa Silva; Carlos Henrique Gomes Martins; Bellisa de Freitas Barbosa; Eloisa Amália Vieira Ferro
Journal:  Sci Rep       Date:  2020-09-16       Impact factor: 4.379

Review 8.  Calomys callosus: An Experimental Animal Model Applied to Parasitic Diseases Investigations of Public Health Concern.

Authors:  Rafael Borges Rosa; Mylla Spirandelli da Costa; Samuel Cota Teixeira; Emilene Ferreira de Castro; Willyenne Marília Dantas; Eloisa Amália Vieira Ferro; Murilo Vieira da Silva
Journal:  Pathogens       Date:  2022-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.